Amicogen, Inc. (KOSDAQ:092040)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Special Enzymes, New Bio Materials, Biopharmaceutical Material, Health and Beauty	54.72B	55.18B	48.67B	47.13B	53.38B
Special Enzymes, New Bio Materials, Biopharmaceutical Material, Health and Beauty Growth	-0.83%	13.37%	3.28%	-11.71%	-23.33%
Treatment for Incurable and Rare Diseases	-	-	-	22.93M	10.09M
Treatment for Incurable and Rare Diseases Growth	-	-	-	127.14%	-
Raw Drug Substance	122.31B	120.22B	107.27B	85.93B	74.05B
Raw Drug Substance Growth	1.74%	12.08%	24.83%	16.04%	18.15%
Consolidation Adjustment	-3.43B	-15.50B	-11.65B	-8.20B	-11.58B
Total	173.60B	159.90B	144.30B	124.88B	115.86B
Total Growth	8.57%	10.82%	15.55%	7.79%	0.59%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
South Korea	26.64B	27.04B	28.21B	95.65B	83.87B
South Korea Growth	-1.48%	-4.15%	-70.51%	14.04%	15.98%
Overseas	146.97B	132.87B	116.09B	29.23B	31.98B
Overseas Growth	10.61%	14.45%	297.10%	-8.59%	-25.39%
Total	173.60B	159.90B	144.30B	124.88B	115.86B
Total Growth	8.57%	10.82%	15.55%	7.79%	0.59%

Source: S&P Global Market Intelligence.